In fact, studies in patients with MASH and fibrosis have shown the efficacy of some FGF21 analogs in improving fibrosis as well as resolving MASH [85,86], and other studies are ongoing in patients with cirrhosis [84]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.